ASH 2020 Update
So. I'm excited we back and we have a lot to get into and the reason for this is that we heard a number of from the american society for hematology conference. That just took place a couple of weeks ago. So we're going to talk about updates from trillium therapeutics tgi therapeutics actinium. Pharma and i wanna do a little bit of a follow on to my video about anna back with regards to their parkinson's disease data so we're going to touch on all of this stuff and Overall is a pretty interesting conference from some of the data. Updates that i saw of course i'm just going to focus on the companies that i'm interested in but then i'm gonna follow it up with a few other updates that we saw that led to huge increases in in their stock price. So have a lot to get into. So i'm just going to get right into it. And i think before we talk about the company's specifically i did just wanna talk a little bit about non-hodgkin's lymphoma and the reason for this is that to companies trillium in focus a lot on this disease and i just want everybody to be up to speed. So i've talked about non-hodgkin's lymphoma in the past. And i showed like a version of this slide. But i've included a few like prices of previously approved drugs for these diseases just so that we all have a bit more context on what we can expect in terms of a proper valuation for the companies. So just we all understand. Non-hodgkin's lymphoma characterizes a group of malignant lymphocytes cancers. These are known as he malignancies and lymphocytes as we know at their b or t cells and these are part of the adaptive immune system. They collect mutations such that they can grow and then deposit in different areas of your body leading to non lymphoma so they're characterized based on where the lymphocytes and of depositing also whether or not they're indolent or aggressive so the inland version are very slow growing. And they're not always emergency such that they don't need to be treated necessarily immediately but they need to be monitored so the decision to treat with any of the different treatments that event lined here is really up to the doctor themself. Now when it comes to aggressive versions of non hodgkin's lymphoma there's obviously more of a drive to treat and to get rid of this cancer because it's leading to significant side effects on the patient so just to give a little bit more context here the prevalence of non hodgkin's lymphoma and this is the all of them. So i'm just including all of them in this calculation it's around twenty cases per one hundred thousand adults and this is around seventy seven thousand patients in the usa per year so it's a significant patient population treatments out there. That exist are pretty numerous. Though so there's chemotherapies immune therapies targeted therapies. And then i also put radiation stem cell transplants. And then just to give a little bit of a description on the different one. So for indolent non hodgkin's lymphoma. Cdl small lymphocytic leukemia lymphoma marginal zone. Lymphoma cutaneous t. cell lymphoma so that would be on the skin now. All of these cancers have been aggressive version. So if the indolent version gets more aggressive it would turn into these types of cancers that include p tcl deal mantle cell lymphoma or burkitt lymphoma. So keep all that in mind. And i did just wanna put here. So i'm showing a chart from various corporate presentation on Talk about them but just to sort of frame What we can expect in terms of objective response rate of what we want some of the approved drugs already. They hit ours in the range of twenty to thirty percent and then the drugs that verizon was looking at they did a little bit better. But when we're looking at whether or not therapy is is good or bad. You need a reference to compare it to so depending on where they are in terms of the line of treatment. They're looking at and the mechanism of action in the side effects. If they can garner in objective response rate of twenty thirty percent in general that is seen as decent or approvable at least for the fda now it comes to price this is also pretty critical because when we're looking at understanding the total value or potential value of a company. We really have to look at the potential addressable market so drugs that have originally like longtime ago been approved for different types of non hodgkin's lymphoma reduction was one of the original ones and right now it's approved for first line non-hodgkin's lymphoma and i didn't get into the details because they do specific indications but generally a course of this treatment for four months costs around thirty nine thousand dollars so that's kind of the the floor and then there's another one here that's approved for second line or greater see. Tcl cost around twenty nine thousand per month in this zelina but then this can go all the way up to. Yes carta which is approved for third-liner deal as a gilead drug and the cost for that is three hundred seventy three thousand dollars per treatment course so there's a big range and the total addressable market for the entirety of non hodgkin's lymphoma is around three point two billion dollars. So you have to think of all of the approved therapies that are out there and if companies are going to try and get drugs on the market you know how much of that three point two billion are. They going to be able to get for their specific drug.